SOD1 and amyotrophic lateral sclerosis: An inducible drug repurposing screening using pluripotent stem cell (iPSC)–derived motor neurons from an ALS patient with an SOD1 mutation identified bosutinib, a tyrosine kinase inhibitor indicated for the treatment of chronic myeloid leukemia, as a drug with potential therapeutic benefits for ALS (Imamura et al., 2017).